Drug Monograph

Drug/Drug Class:	**Panzyga® (immune globulin intravenous, human - ifas) liquid preparation / Primary and Secondary Immunodeficiency Agent**
Prepared for:	MO HealthNet
Prepared by:	Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Panzyga® is available as a 10% liquid in several intravenous single-use bottles. The sizes available are: 10 mL, 25 mL, 50 mL, 100 mL, 200 mL and 300 mL.
Manufacturer:	Distributed by: Octapharma USA Inc., Hoboken, NJ 07030.
Indications:	Panzyga® is indicated for the treatment of primary humoral immunodeficiency (PI) in patients 2 years or age and older and chronic immune thrombocytopenia (ITP) in adults.
Costs:	$4,959 per vial for Panzyga® 10% liquid. Maximum Allowable Cost
Summary of Findings:	MO HealthNet Division recommends Open Access status for this product.
Status Recommendation:	☐ Prior Authorization (PA) Required ☒ Open Access ☐ Fiscal Edit ☐ Clinical Edit
Type of PA Criteria:	☐ Increased Risk of ADE ☐ Preferred ☐ Appropriate Indications ☒ No PA Required

Prepared By: Tyler Woods PharmD
Date: January 28, 2019

© 2019 Conduent Business Services, LLC All Rights Reserved.